Tumor endothelial cell-derived cadherin-2 promotes angiogenesis and has prognostic significance for lung adenocarcinoma

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape

(2017) Hawazin Faruki et al.   Journal of Thoracic Oncology

The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition

(2017) Justin Goodwin et al.   Nature Communications

Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm

(2016) Benjamin F. Chu et al.   Clinical Lung Cancer

Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy

(2015) Ya-Rong Liu et al.   BIOMATERIALS

Effect of Lung Squamous Cell Carcinoma Tumor Microenvironment on the CD105+ Endothelial Cell Proteome

(2014) Huiqin Zhuo et al.   JOURNAL OF PROTEOME RESEARCH

Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches

(2014) Wen Zhang et al.   PROTEOMICS

Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours

(2009) A. Perotti et al.   ANNALS OF ONCOLOGY